Buradasınız

FORMULATION AND EVALUATION OF BILAYERED TABLET OF METFORMIN HYDROCHLORIDE AND GLIMEPIRIDE

Journal Name:

Publication Year:

Abstract (2. Language): 
An attempt was to formulate Pharmaceutical equivalent bilayer tablet of Anti-diabetic by using the wet granulation method. In this formula one layer provide the loading dose by immediate drug release and another layer provide maintenance dose up to 10 hrs by extended release. The drug excipient computability study was carried out with FTIR study, there was no interaction found. Immediate release fraction was formulated by using cross carmellose sodium (CCS) as a disintegrating agent and sustained release fraction was formulated by using hydroxy propyl methyl cellulose (HPMC) as a rate controlling polymer. The granules were evaluated for angle of repose, bulk density, tapped density and compressibility index showed satisfactory results. The prepared bilayer tablets were evaluated as thickness, hardness, friability and in-vitro release studies. In-vitro dissolution study was carried out for 10 hrs using USP dissolution apparatus type II with 0.1 N HCl and 6.8 pH phosphate buffer as dissolution medium. From the Kinetic study of dissolution profile all batches were depicted for release mechanism of sustained release. Stability study was carried out for the optimized formulation at 40°C/75% RH for 1 month, the result shows that there was no significant change in physical and chemical parameter of the tablet.
FULL TEXT (PDF): 
75-87

REFERENCES

References: 

1. Hilleman DE, Ryschon KL, Mohiuddin SM and Wurderman RL: Fixed dose combination vs monotherapy in diabetes. J. of Human Diabetes. 1999; 13: 477-483.
2. Drug Bank, http://www.drugbank.ca/drugs/DB00178 June 2008.
3. Drug detail, http://en.wikipedia.org/wiki/MetforminHCl &Glimepiride June 2010.
4. Satoskar RS, Bhadrakar SD and Ainapure SS: Pharmacotherapy of diabetes; 14th edition, 1995: 358-359.
5. Joseph RR: Sustained and controlled release drug delivery systems; Marcel and
Dekkar, New York, Basel: 1, 4, 6, 9, 10, 14, 15.
6. William CG, Dusel RG, Lieberman HA and Lachman L: Pharmaceutical Dosage Forms; 3rd edition; New York: 273-276.
7. National Diabetes Data Group, Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes, 1979; 28: 1039-57.
8. Lim JC and Shell JN, Manufacture of oral dosage forms delivering both immediate - release and sustained-release drugs, 2004: 300.
9. Robinson JR and Lee VH: Influence of Drug properties and Routes of Drug
Available Online At www.ijprbs.com
Research
Article
Ghanshyam Patel, IJPRBS, 2012; Volume 1(6): 75-87
Administration on the Design of Sustained Pump. and Controlled release System 2nd edition: 1991. 312.
10. Rang HP, Dale MM and Moore PK: Antidiabetic agents, Pharmacology, 5th edition, Churchill Livingstone, 2003: 254¬297.
11. Asgar A and Sharma SN: Evaluation of oral sustained release formulation, The Eastern Pharmacist, 1991: 69-74.
12. Vyas SP and Khar RK: Controlled drug delivery, concepts and advances, 1st edition, Vallabh prakashan, 2002: 150- 167.
13. Qiu Y and Zhang G: Research and Development Aspects of Oral Controlled-Release dosage Forms in Handbook of Pharmaceutical Controlled Release Technology (Wise, D. L Edt), Marcel Dekker Inc, 2000.
14. Aditya ST, Ketan AM, Larry LA and Stephen WH: Influence of methacrylic and Acrylic acid polymers on the release performance of weakly basic drugs from sustained release hydrophilic matrix. Int. J. Pharm. sci. 2004; 93: 2319-2331.
15. Theeuwes F: Elementary Osmotic
ISSN: 2277-8713
IJPRBS
Int. J. Pharm. sci. 1995; 64: 1987¬
16. Yie W and Chien: Rate controlled drug
delivery systems, 2n d edition, Marcel
Dekker Revised and expanded, 2005.
17. Brahmankar D and Jaiswal S:
Biopharmaceutics and Pharmacokinetics a
Treatise, 1s t edition, Vallabh Prakashan,
New Delhi: 335-346.
Available Online

Thank you for copying data from http://www.arastirmax.com